EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis

Abstract

BackgroundOur goal was to investigate the prevalence of the epidermal growth factor receptor (EGFR) mutation in Middle East and African countries and to compare its prevalence with that shown in other populations.MethodsWe used PubMed and the Cochrane Library databases to conduct a literature search using the terms “[EGFR] AND [mutation] AND [Non Small Cell Lung Cancer] AND [Middle East OR Africa].” We assessed studies published in English and French from 2004 until 2016.ResultsTen relevant studies were included in this systematic review. Overall, 1215 patients with non-small cell lung cancer (NSCLC) were included in this analysis. The overall ratio of male to female patients was 2.15. Of total patients included, 41.1% had never smoked and 85.8% had been diagnosed with adenocarcinoma. In 8 of the 10 studies, polymerase chain reaction (PCR) analyses were conducted to identify EGFR mutations. In total, 257 patients had an EGFR mutation, corresponding to a prevalence of 21.2%. The most frequent abnormality detected in all of the studies was in exon 19. In addition, all studies concluded the presence of a correlation between EGFR mutation status and female sex, non-smoking status, and adenocarcinoma subtype.ConclusionsThe EGFR mutation frequency in Middle East and African patients is higher than that shown in white populations but still lower than the frequency reported in Asian populations.

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

“…Frequencies in Middle East and African populations are slightly higher than those observed in Western populations but still lower than in Asian populations. A slightly lower prevalence has been observed in the Oceanic ethnicities and other insular Mediterranean populations (12%) [ 19 , 24 , 25 ].…”

Lung Cancer in South Africa

“…The data on EGFR mutations in Africa as a whole seem to be consistent with the current literature on such mutations in Western countries. 4 According to a 2014 retrospective study, EGFR mutations were present in 21.3% of South African patients. 5 Exon 20 mutations were detected more frequently in Africa and the Middle East than in Europe.…”

Mutation Analysis of EGFR Gene in Patients with Non-Small Cell Lung Cancer in Xinjiang

“…Another study in Europe about the EGFR mutations in 162 patients with NSCLC were analyzed, and the results showed that The mutation rate of EGFR is 24.7%. By comparing similar studies at home and abroad, It was found that the mutation rate in Chinese patients with NSCLC was higher than that in Europe and the United States [24], but the mutation rate in patients with NSCLC is similar with Asia and Japan. The lung cancer of Uygur population in Xinjiang has its own pathogenic characteristics, Shenhongli and others in 2013 detected the dimension In the case of man and Han EGFR mutations [25], Uygur mutation rate was 10.8%, With the Han mutation rate of 44%.…”